1. Hezam AAM, Shaghdar HBM, Chen L. The connection between hypertension and diabetes and their role in heart and kidney disease development. Journal of Research in Medical Sciences. 2024;29(1):22. DOI: 10.4103/jrms.jrms_470_23
2. Wong ND, Sattar N. Cardiovascular risk in diabetes mellitus: epidemiology, assessment and prevention. Nature Reviews Cardiology. 2023;20(10):685–95. DOI: 10.1038/s41569-023-00877-z
3. Hauwanga WN, Abdalhamed TY, Ezike LA, Chukwulebe IS, Ko Oo A, Wilfred A et al. The Pathophysiology and Vascular Complications of Diabetes in Chronic Kidney Disease: A Comprehensive Review. Cureus. 2024;16(12): e76498. DOI: 10.7759/cureus.76498
4. International Diabetes Federation. IDF Diabetes Atlas 10th edition 2021. [Internet] Available at: https://idf.org/news-and-resources/resources/idf-diabetesatlas-2021/.
5. World Health Organization. Global health estimates: Leading causes of death. Cause-specific mortality, 2000–2021. [Internet] Available at: https://www.who.int/data/gho/data/themes/mortality-and-global-health-estimates/ghe-leading-causes-of-death
6. World Health Organization. Age-standardized prevalence of hypertension among adults aged 30 to 79 years (%). [Internet] Available at: https://data.who.int/indicators/i/7DA4E68/608DE39.
7. Zhang R, Mamza JB, Morris T, Godfrey G, Asselbergs FW, Denaxas S et al. Lifetime risk of cardiovascularrenal disease in type 2 diabetes: a population-based study in 473,399 individuals. BMC Medicine. 2022;20(1):63. DOI: 10.1186/s12916-022-02234-2
8. Баширов А.У Эпидемиология хронической сердечной недостаточности в Казахстане и других странах. Ульяновский медико-биологический журнал. 2024;3:17–27. DOI: 10.34014/2227-1848-2024-3-17-27
9. Burnier M, Damianaki A. Hypertension as Cardiovascular Risk Factor in Chronic Kidney Disease. Circulation Research. 2023;132(8):1050–63. DOI: 10.1161/CIRCRESAHA.122.321762
10. Weldegiorgis M, Woodward M. The impact of hypertension on chronic kidney disease and end-stage renal disease is greater in men than women: a systematic review and meta-analysis. BMC Nephrology. 2020;21(1):506. DOI: 10.1186/s12882-020-02151-7
11. Pagidipati NJ, Deedwania P. A Comprehensive Cardiovascular-Renal-Metabolic Risk Reduction Approach to Patients with Type 2 Diabetes Mellitus. The American Journal of Medicine. 2021;134(9):1076–84. DOI: 10.1016/j.amjmed.2021.04.024
12. Preda A, Montecucco F, Carbone F, Camici GG, Lüscher TF, Kraler S et al. SGLT2 inhibitors: from glucose-lowering to cardiovascular benefits. Cardiovascular Research. 2024;120(5):443–60. DOI: 10.1093/cvr/cvae047
13. Singh H, Puckett C, Lucas YQ. Integrating and Simplifying Evidence to Optimize Cardiorenal Guideline-Directed Therapies. Journal of Clinical Medicine. 2025;14(16):5883. DOI: 10.3390/jcm14165883
14. Szczech LA, Stewart RC, Su H-L, DeLoskey RJ, Astor BC, Fox CH et al. Primary Care Detection of Chronic Kidney Disease in Adults with Type-2 Diabetes: The ADD-CKD Study (Awareness, Detection and Drug Therapy in Type 2 Diabetes and Chronic Kidney Disease). PLoS ONE. 2014;9(11): e110535. DOI: 10.1371/journal.pone.0110535
15. Tangri N, Peach EJ, Franzén S, Barone S, Kushner PR. Patient Management and Clinical Outcomes Associated with a Recorded Diagnosis of Stage 3 Chronic Kidney Disease: The REVEAL–CKD Study. Advances in Therapy. 2023;40(6):2869–85. DOI: 10.1007/s12325-023-02482-5
16. Нурсултанова Л. Н. Распространенность хронической болезни почек в Казахстане (обзор литературы). Вестник Казахского Национального Медицинского Университета. 2020;4:291–4.
17. AstraZeneca. iCaReMe Global Registry: Multinational Real-world Evidence in Cardiorenal and Metabolic Diseases (iCaReMe). NCT03549754. 2026. [Internet] Available at: https://clinicaltrials.gov/study/NCT03549754?term=Africa.
18. Khunti K, Heerspink HJL, Lam CSP, Nicolucci A, Ramirez L, Surmont F et al. Design and rationale of DISCOVER global registry in type 2 diabetes: Real-world insights of treatment patterns and its relationship with cardiovascular, renal, and metabolic multimorbidities. Journal of Diabetes and its Complications. 2021;35(12):108077. DOI: 10.1016/j.jdiacomp.2021.108077
19. Reddy YNV, Carter RE, Obokata M, Redfield MM, Borlaug BA. A Simple, Evidence-Based Approach to Help Guide Diagnosis of Heart Failure With Preserved Ejection Fraction. Circulation. 2018;138(9):861–70. DOI: 10.1161/CIRCULATIONAHA.118.034646
20. Pieske B, Tschöpe C, de Boer RA, Fraser AG, Anker SD, Donal E et al. How to diagnose heart failure with preserved ejection fraction: the HFA–PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). European Heart Journal. 2019;40(40):3297–317. DOI: 10.1093/eurheartj/ehz641
21. World Health Organization. Obesity: preventing and managing the global epidemic: report of a WHO consultation. – Geneva: World Health Organization; 2000. – 253p. ISBN 978-92-4-120894-9
22. Ожирение у взрослых. Клинические протоколы МЗ РК – 2023 (Казахстан). Доступно на: https://diseases.medelement.com/disease/ожирение-у-взрослых-кп-рк-2023/17781
23. Von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies. PLoS Medicine. 2007;4(10): e296. DOI: 10.1371/journal.pmed.0040296
24. Ndumele CE, Rangaswami J, Chow SL, Neeland IJ, Tuttle KR, Khan SS et al. Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association. Circulation. 2023;148(20):1606–35. DOI: 10.1161/CIR.0000000000001184
25. ESC cardiovascular statistics. ESC Atlas of Cardiology. Lifestyle risk factors. Daily smoking, both (% population aged 15+, age-standardized). [Internet] Available at: https://eatlas.escardio.org/Data/Risk-factors/Lifestyle-risk-factors/rf_smok_daily_std_t_p-daily-smoking-both-population-aged-15-age-standardiz.
26. Lund LH, Maggioni AP, Crespo-Leiro MG, Laroche C, Gotsman I, Pojskic B et al. Outcomes of heart failure with reduced, mildly reduced, or preserved ejection fraction: the ESC HF III registry. European Heart Journal. 2026;47(19):2326–41. DOI: 10.1093/eurheartj/ehaf1074
27. Greene SJ, Butler J, Albert NM, DeVore AD, Sharma PP, Duffy CI et al. Medical Therapy for Heart Failure With Reduced Ejection Fraction: The CHAMP-HF Registry. Journal of the American College of Cardiology. 2018;72(4):351–66. DOI: 10.1016/j.jacc.2018.04.070
28. Wanner C, Schaeffner E, Frese T, Opfermann U, Radowsky F, Stahl P et al. InspeCKD: an analysis of the prevalence, diagnosis, and treatment of chronic kidney disease: Data from at-risk patients in German primary care. Die Innere Medizin. 2025;66(10):1087–99. DOI: 10.1007/s00108-025-01958-6
29. Tomek J, Bub G. Hypertension‐induced remodelling: on the interactions of cardiac risk factors. The Journal of Physiology. 2017;595(12):4027–36. DOI: 10.1113/JP273043
30. Law JP, Pickup L, Pavlovic D, Townend JN, Ferro CJ. Hypertension and cardiomyopathy associated with chronic kidney disease: epidemiology, pathogenesis and treatment considerations. Journal of Human Hypertension. 2023;37(1):1–19. DOI: 10.1038/s41371-022-00751-4
31. Palaniappan LP, Wong EC, Shin JJ, Fortmann SP, Lauderdale DS. Asian Americans have greater prevalence of metabolic syndrome despite lower body mass index. International Journal of Obesity. 2011;35(3):393–400. DOI: 10.1038/ijo.2010.152
32. Powell-Wiley TM, Poirier P, Burke LE, Després J-P, Gordon-Larsen P, Lavie CJ et al. Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation. 2021;143(21): e984–1010. DOI: 10.1161/CIR.0000000000000973
33. Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP et al. Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. New England Journal of Medicine. 2019;381(17):1609–20. DOI: 10.1056/NEJMoa1908655
34. Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B et al. Spironolactone for Heart Failure with Preserved Ejection Fraction. New England Journal of Medicine. 2014;370(15):1383–92. DOI: 10.1056/NEJMoa1313731